NIH Registers Phase 1 T2DM Oxidative Stress Study
Summary
NIH has registered a Phase 1 clinical trial (NCT07541729) on ClinicalTrials.gov evaluating Rosmarinus officinalis (rosemary) extract in patients with Type 2 Diabetes Mellitus (T2DM). The 12-week randomized study will assess the extract's effects on oxidative stress and inflammatory biomarkers versus placebo. Participants will be randomly assigned to receive either rosemary extract or placebo for the study duration.
What changed
NIH registered a Phase 1 clinical trial (NCT07541729) on ClinicalTrials.gov, described as a randomized, placebo-controlled study investigating the effects of Rosmarinus officinalis (rosemary) extract on oxidative stress and inflammatory biomarkers in patients with Type 2 Diabetes Mellitus over 12 weeks.
Pharmaceutical companies, clinical investigators, and healthcare providers with interest in diabetes research or botanical extract therapeutics should note this trial as informational. No compliance obligations, deadlines, or penalties are associated with this registry entry.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Effect of Rosmarinus Officinalis Extract on Oxidative Stress and Inflammatory Biomarkers in Patients With Type 2 Diabetes(T2DM)
Phase 1 NCT07541729 Kind: PHASE1 Apr 21, 2026
Abstract
This study will evaluate the effects of Rosmarinus officinalis (rosemary) extract on oxidative stress and inflammation in patients with type 2 diabetes. Participants will be randomly assigned to receive either rosemary extract or a placebo for 12 weeks. The study aims to determine whether rosemary extract can improve health markers related to oxidative stress, inflammation, and metabolic function.
Conditions: Type 2 Diabetes Mellitus (T2DM), Oxidative Stress, Inflammation Chronic
Interventions: Placebo, Rosmarinus officinalis extract
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.